Intellectual Property India Publishes Patent Application for P53-Senodef: A Senescence-Decoupled Apoptosis-Selective And Ferroptosis-Retaining Engineered Tp53 Variant With Six Point Mutations Delivered Via Beta-Sitosterol Dope Lipid Nanoparticles With P28 Cell-Penetrating Peptide And Folate Targeting For Non-Viral Protein And Mrna-Based Triple-Mechanism Cancer Therapy Without Accelerating Tissue Ageing

MUMBAI, India, July 30 -- Intellectual Property India has published a patent application (202641050877 A) filed by Dev Sudersan on April 21, 2026, for P53-Senodef: A Senescence-Decoupled Apoptosis-Selective And Ferroptosis-Retaining Engineered Tp53 Variant With Six Point Mutations Delivered Via Beta-Sitosterol Dope Lipid Nanoparticles With P28 Cell-Penetrating Peptide And Folate Targeting For Non-Viral Protein And Mrna-Based Triple-Mechanism Cancer Therapy Without Accelerating Tissue Ageing.

Inventor includes Dev Sudersan.

The application for the patent was published on July 24, 2026, under issue no. 30/2026.

Abstract: The present invention relates to p53-SenoDef-v2, a computationally engineered recombinant human TP53 protein variant com...